Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsors and Collaborators: |
Astellas Pharma Inc Astellas Pharma US, Inc. |
---|---|
Information provided by: | Astellas Pharma Inc |
ClinicalTrials.gov Identifier: | NCT00102310 |
The primary objective of this study will be to characterize the dose response profile of YM443 in subjects with functional dyspepsia (FD) to enable the selection of doses for the Phase 3 clinical trial.
Condition | Intervention | Phase |
---|---|---|
Indigestion Nausea |
Drug: YM443 |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Dose Ranging Study of YM443 in Subjects With Functional Dyspepsia |
Ages Eligible for Study: | 18 Years to 75 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Medical Monitor | APUS |
Study ID Numbers: | 443-CL-008 |
Study First Received: | January 26, 2005 |
Last Updated: | December 19, 2007 |
ClinicalTrials.gov Identifier: | NCT00102310 |
Health Authority: | United States: Food and Drug Administration |
Nausea Indigestion Bloating Functional Dyspepsia Fullness after Meals |
Signs and Symptoms Stomach Diseases Digestive System Diseases Signs and Symptoms, Digestive Gastrointestinal Diseases |
Nausea Gastroenteritis Dyspepsia Gastritis |